Filing Flows › Prime Medicine (PRME) › Q4 2025 › vs Q4 2024
Prime Medicine (PRME) Q4 2025 vs Q4 2024 (year over year)
Prime Medicine's revenue fell $1.3M (-62%) from $2.2M in Q4 2024 to $838K in Q4 2025.
Prime Medicine, Q4 2025: revenue $838K (-62% year over year), net loss $46.1M, operating cash flow −$37.3M. The chart draws each line against Q4 2024, the increases inside each band.
Every line
| Line | Q4 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $838K | $2.2M | −$1.3M | -62% |
| Other income, net | $2.5M | $1.9M | $583K | +30% |
| Net loss | $46.1M | $42.3M | $3.8M | +9% |
| Costs & expenses | $49.4M | $46.4M | $3.0M | +7% |
| Operating costs | $49.4M | $46.4M | $3.0M | +7% |
| Research & development | $34.7M | $34.1M | $605K | +2% |
| General & admin | $14.7M | $12.3M | $2.4M | +20% |
| Operating cash sources | $46.1M | $42.3M | $3.8M | +9% |
| Depreciation & amortization | $1.9M | $1.7M | $159K | +9% |
| Share-based compensation | $4.5M | $5.9M | −$1.4M | -24% |
| Working capital & other | $2.4M | $50.9M | −$48.4M | -95% |
| Cash used in operations | $37.3M | −$16.2M | $53.5M | — |
| Net loss absorbed | $46.1M | $42.3M | $3.8M | +9% |
Questions
How much did Prime Medicine's revenue grow year over year in Q4 2025?
Prime Medicine's revenue fell $1.3M (-62%) from $2.2M in Q4 2024 to $838K in Q4 2025.